TRPA1 antibody, method for preparing the same and application thereof

The nanodisc packaging purification protein and hybridoma technology screening was performed to prepare high affinity and functional TRPA1 antibodies, which solved the problem of poor performance of existing TRPA1 antibodies, achieved effective antagonism of TRPA1, and provided a potential pain treatment plan.

CN117886941BActive Publication Date: 2024-11-19SHENZHEN CRYSTALO BIOPHARMA TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410084491.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-19
Publication Date
2024-11-19
Estimated Expiration
2044-01-19

AI Technical Summary

Technical Problem

The prior art lacks functionally active antibodies targeting TRPA1, and the existing TRPA1 antibodies have poor affinity, specificity and functionality, making it difficult to effectively treat pain and other indications.

Method used

The purified proteins were used to package nanodisc as immunogens to prepare TRPA1 antibodies through hybridoma technology. Antibodies with high affinity and functionality were screened using ELISA and FACS. The fluorescence intensity changes caused by calcium influx intracellular were read in combination with FlexStation3, and the fluorescence intensity changes caused by influx intracellular calcium ions were screened out. Antibodies with TRPA1 antagonistic function.

Benefits of technology

The obtained TRPA1 antibody has high affinity for TRPA1, with IC50 below 1.54μM and a minimum of 0.56μM, which significantly inhibits the activation of TRPA1 channel and provides an effective pain treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117886941B_ABST
    Figure CN117886941B_ABST
Patent Text Reader

Abstract

The present invention discloses a TRPA1 antibody, a method for preparing the same and an application thereof, wherein the TRPA1 antibody comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, the amino acid sequences of which are shown in SEQ ID NO:56-58 respectively; and / or the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequences of which are shown in SEQ ID NO:59, SEQ ID NO:9 and SEQ ID NO:10 respectively. The TRPA1 antibody provided by the present invention has a relatively high affinity for TRPA1, and the screened TRPA1 antibody has a significant inhibitory effect on the TRPA1 channel activated by AITC, and its IC50 is lower than 1.54 μM, and the lowest can reach 0.56 μM.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a TRPA1 antibody, a method for preparing the same and an application thereof. Background Art

[0002] Transient receptor potential ankyrin subtype 1 protein (TRPA1) is a Ca-permeable 2+ 、Na + and K + TRPA1 is a non-selective cation channel. It is present in a subset of Aδ-fiber and C-fiber nociceptive sensory neurons and in other sensory cells including epithelial cells. In primary sensory neurons, Ca 2+ and Na + It flows into cells through TRPA1, causing membrane depolarization, action potential firing, and neurotransmitter release in peripheral and central neural projections.

[0003] In addition to being activated by cysteine- and lysine-reactive electrophiles and oxidants, TRPA1 can also be indirectly activated by proinflammatory agents via the phospholipase C signaling pathway, in which cytosolic Ca 2+ It is an important regulator of channel gating.

[0004] Multiple lines of evidence implicate TRPA1 in pain perception. TRPA1 is expressed in sensory neurons and colocalizes with pain markers such as TRPV1 and bradykinin receptors. Its expression is increased in animal models of inflammatory and neuropathic pain, as well as in human DRG neurons following avulsion injury. TRPA1 agonists induce neurotransmitter release, pain, and inflammation in rodents and humans, while endogenous agonists such as 4-HNE are elevated in human pathological conditions. In several animal models, gene knockout attenuates agonist sensitivity and antagonist treatment reduces pain. TRPA1 is thought to play a role in many sensory modalities, including chemical nociception, mechanical nociception, and cold nociception.

[0005] In recent years, opioid addiction and overdose have increased at an alarming rate and have become a serious national crisis in the United States, resulting in many deaths every day. Today more than ever, the development of new non-opioid pain medications without addiction potential is needed. Because TRPA1 is involved in chronic and acute pain, TRPA1 antagonists have the potential to provide the next generation of pain medications that could help alleviate the current opioid crisis.

[0006] Research on the indications of TRPA1 for the treatment of pain, skin diseases, and respiratory diseases such as asthma is quite hot. TRPA1 small molecule antagonists mainly include structures such as xanthine, sulfonamide, oxadiazolone, oxadiazole and carboxamide. As of 2019, five small molecules have entered the clinic but all have been terminated due to poor pharmacokinetic properties. Compared with small molecule drugs, large molecule antibody drugs have obvious advantages. Their limited central nervous system (CNS) permeability (when targeting peripheral treatment), low immunogenicity, high selectivity and favorable half-life make the antibody development of TRPA1 an attractive alternative to biologics. However, due to the dynamic nature of the TRPA1 conformation and the extremely small extracellular region, screening for functionally active antibodies remains a well-known challenge. The existing commercially available TRPA1 antibodies are mainly polyclonal antibodies used in TRPA1 immunological detection experiments, and their affinity, specificity, functionality and other properties are poor. Summary of the invention

[0007] In order to solve the problem of lack of functional active antibodies targeting TRPA1 in the prior art, the present invention provides a TRPA1 antibody, a method for preparing the same and its application. The immunogen used in the preparation process is a protein packaged and purified by nanodisc. The antibody is prepared by hybridoma technology. The affinity screening is mainly ELISA and FACS. Combined with flexstation3, the fluorescence intensity changes caused by calcium ions flowing into the cell through ion channels are read to screen out antibodies with both affinity and functionality. Several therapeutic antibodies with TRPA1 antagonistic function are obtained through affinity testing, functional testing, sequence acquisition and other work.

[0008] In order to solve the above technical problems, the first aspect of the present invention provides a TRPA1 antibody, wherein the TRPA1 antibody comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs:56-58, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs:59, 9 and 10, respectively; or,

[0009] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 26-28, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 29-31, respectively; or,

[0010] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 36-38, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 39-41, respectively; or,

[0011] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs:51-53, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs:54, SEQ ID NO:30 and SEQ ID NO:55, respectively.

[0012] In some embodiments of the present invention, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 5-7, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 8-10, respectively; or,

[0013] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 17-19, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 8-10, respectively; or,

[0014] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 17-19, respectively; and / or, the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 46, 9 and 10, respectively.

[0015] In some embodiments of the present invention, the heavy chain variable region also includes a heavy chain variable region framework region HFWR, and / or the light chain variable region also includes a light chain variable region framework region LFWR, wherein the HFWR is a heavy chain variable region framework region of human or mouse origin, and the LFWR is a light chain variable region framework region of a human or mouse antibody.

[0016] In some preferred embodiments of the present invention, the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:4 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:4; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:3 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:3; or,

[0017] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 14, or is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence as shown in SEQ ID NO: 14; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 13, or is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence as shown in SEQ ID NO: 13; or,

[0018] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 14, or is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence as shown in SEQ ID NO: 14; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 16, or is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence as shown in SEQ ID NO: 16; or,

[0019] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 14 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO: 14; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 21 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO: 21; or,

[0020] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:25 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:25; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:24 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:24; or,

[0021] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:35 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:35; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:34 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:34; or,

[0022] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:45 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:45; and / or, the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:44 or has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the amino acid sequence as shown in SEQ ID NO:44; or,

[0023] The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:50 or is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence as shown in SEQ ID NO:50; and / or the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:49 or is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence as shown in SEQ ID NO:49.

[0024] In some more preferred embodiments of the present invention, the TRPA1 antibody further comprises a heavy chain constant region and a light chain constant region.

[0025] In some further more preferred embodiments of the present invention, the TRPA1 antibody heavy chain constant region is a human or mouse antibody heavy chain constant region; the TRPA1 antibody light chain constant region is a human or mouse antibody light chain constant region.

[0026] In some embodiments of the present invention, the TRPA1 antibody is in any of the following antibody forms:

[0027] (a) a complete immunoglobulin molecule;

[0028] (b) a scFv;

[0029] (c) a fusion protein comprising scFv;

[0030] (d) a Fab fragment;

[0031] (e) a Fab′ fragment;

[0032] (f) a F(ab)2;

[0033] Alternatively, the TRPA1 antibody is a monoclonal antibody or a polyclonal antibody;

[0034] Alternatively, the TRPA1 antibody is a humanized antibody or a bispecific antibody.

[0035] In order to solve the above technical problem, the second aspect of the present invention provides a chimeric antigen receptor, which comprises the TRPA1 antibody as described in the first aspect of the present invention.

[0036] In order to solve the above technical problems, the third aspect of the present invention provides an isolated nucleic acid encoding the TRPA1 antibody as described in the first aspect of the present invention, or the chimeric antigen receptor as described in the second aspect of the present invention.

[0037] In some preferred embodiments of the present invention, the nucleic acid encoding the TRPA1 antibody comprises a polynucleotide sequence as shown in SEQ ID NO:1 and / or as shown in SEQ ID NO:2; or, comprises a polynucleotide sequence as shown in SEQ ID NO:11 and / or as shown in SEQ ID NO:12; or, comprises a polynucleotide sequence as shown in SEQ ID NO:15 and / or as shown in SEQ ID NO:12; or, comprises a polynucleotide sequence as shown in SEQ ID NO:20 and / or as shown in SEQ ID NO:12; or, comprises a polynucleotide sequence as shown in SEQ ID NO:22 and / or as shown in SEQ ID NO:23; or, comprises a polynucleotide sequence as shown in SEQ ID NO:32 and / or as shown in SEQ ID NO:33; or, comprises a polynucleotide sequence as shown in SEQ ID NO:42 and / or as shown in SEQ ID NO:43; or, comprises a polynucleotide sequence as shown in SEQ ID NO:47 and as shown in SEQ ID NO:48.

[0038] In order to solve the above technical problems, the fourth aspect of the present invention provides a recombinant expression vector comprising the isolated nucleic acid as described in the third aspect of the present invention.

[0039] In order to solve the above technical problems, the fifth aspect of the present invention provides a transformant, which contains the recombinant expression vector as described in the fourth aspect in a host cell.

[0040] In order to solve the above technical problems, the sixth aspect of the present invention provides a method for preparing a TRPA1 antibody, which comprises culturing the transformant as described in the fifth aspect of the present application, and obtaining the TRPA1 antibody from the culture.

[0041] In order to solve the above technical problems, the seventh aspect of the present invention provides an antibody-drug conjugate, which comprises a cytotoxic agent and the TRPA1 antibody as described in the first aspect of the present invention.

[0042] In order to solve the above technical problems, the eighth aspect of the present invention provides a pharmaceutical composition, which comprises the TRPA1 antibody as described in the first aspect of the present invention, the chimeric antigen receptor as described in the second aspect of the present invention or the antibody-drug conjugate as described in the seventh aspect of the present invention, and a pharmaceutically acceptable carrier.

[0043] In order to solve the above technical problems, the ninth aspect of the present invention provides the use of the TRPA1 antibody as described in the first aspect of the present invention, the chimeric antigen receptor as described in the second aspect of the present invention, the isolated nucleic acid as described in the third aspect of the present invention, the recombinant expression vector as described in the fourth aspect of the present invention, the transformant as described in the fifth aspect of the present invention, the antibody-drug conjugate as described in the seventh aspect of the present invention, or the pharmaceutical composition as described in the eighth aspect of the present invention in the preparation of a drug for treating pain.

[0044] In some preferred embodiments of the present invention, the pain is pain caused by activation of TRPA1; and the target of the drug is TRPA1.

[0045] In order to solve the above technical problems, the tenth aspect of the present invention provides a kit, which includes the TRPA1 antibody as described in the first aspect of the present invention, the chimeric antigen receptor as described in the second aspect of the present invention, the antibody-drug conjugate as described in the seventh aspect of the present invention and / or the pharmaceutical composition as described in the eighth aspect of the present invention.

[0046] In order to solve the above technical problems, the eleventh aspect of the present invention provides a method for detecting TRPA1, which comprises contacting a sample with the TRPA1 antibody as described in the first aspect of the present invention, the chimeric antigen receptor as described in the second aspect of the present invention, the antibody-drug conjugate as described in the seventh aspect of the present invention, the pharmaceutical composition as described in the eighth aspect of the present invention and / or the kit as described in the tenth aspect of the present invention.

[0047] In some preferred embodiments of the present invention, the detection is for non-diagnostic purposes.

[0048] In order to solve the above technical problems, the twelfth aspect of the present invention provides a method for treating and / or preventing pain, which comprises administering to a patient in need thereof a therapeutically effective amount of the TRPA1 antibody as described in the first aspect of the present invention, the chimeric antigen receptor as described in the second aspect of the present invention, the isolated nucleic acid as described in the third aspect of the present invention, the recombinant expression vector as described in the fourth aspect of the present invention, the transformant as described in the fifth aspect of the present invention, the antibody-drug conjugate as described in the seventh aspect of the present invention, the pharmaceutical composition as described in the eighth aspect of the present invention and / or the kit as described in the tenth aspect of the present invention.

[0049] In some preferred embodiments of the present invention, the pain is pain caused by activation of TRPA1; and the target of the drug is TRPA1.

[0050] In order to solve the above technical problems, the thirteenth aspect of the present invention provides the TRPA1 antibody as described in the first aspect of the present invention, the chimeric antigen receptor as described in the second aspect of the present invention, the isolated nucleic acid as described in the third aspect of the present invention, the recombinant expression vector as described in the fourth aspect of the present invention, the transformant as described in the fifth aspect of the present invention, the antibody-drug conjugate as described in the seventh aspect of the present invention, the pharmaceutical composition as described in the eighth aspect of the present invention and / or the kit as described in the tenth aspect of the present invention, which are used for treating and / or preventing pain.

[0051] In some preferred embodiments of the present invention, the pain is pain caused by activation of TRPA1; and the target of the drug is TRPA1.

[0052] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0053] The reagents and raw materials used in the present invention are commercially available.

[0054] The positive and progressive effect of the present invention is that the anti-TRPA1 antibody provided by the present invention has a relatively high affinity for TRPA1, and the screened antibody has a significant inhibitory effect on the TRPA1 channel activated by AITC, with an IC50 lower than 1.54 μM and a minimum of 0.56 μM. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 This is the map of the pEGBacMam recombinant plasmid containing TRPA1 and MBP.

[0056] Figure 2 This is the map of the pET 28a recombinant plasmid containing MSP2N2.

[0057] Figure 3 The figure shows the purification result of TRPA1-Nanodisc protein.

[0058] Figure 4 These are the titer test results of the 4th and 5th sera from mice immunized with TRPA1-Nanodisc protein.

[0059] Figure 5a-5h The following are the ELISA test results of the 8 antibodies obtained by screening.

[0060] Figure 6a-6h This is the FACS test result of the 8 antibodies obtained by screening.

[0061] Figure 7 This is the SDS-PAGE picture of the 8 antibodies obtained after purification.

[0062] Figures 8a-8i The positive small molecule A967079 and the 8 screened antibodies have inhibitory effects on TRPA1 channel current. DETAILED DESCRIPTION

[0063] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0064] Example 1 Preparation of recombinant baculovirus

[0065] 1.1 Obtaining recombinant baculovirus plasmid

[0066] By heat shock transformation, the recombinant pEGBacMam plasmid containing the target gene (synthesized by Nanjing Qingke Biotechnology Co., Ltd., carrying EcoR1 and Not1 restriction sites) was ligated and recombined into the pEGBacMam plasmid. The pEGBacMam recombinant plasmid containing TRPA1 and MBP was as follows: Figure 1 As shown, the pET 28a recombinant plasmid containing MSP2N2 is as follows Figure 2coli DH10Bac competent cells (Shanghai Weidi), cultured at 37°C for 48-72 hours in LB solid medium containing 50μg / mL kanamycin (aladdin), 7μg / mL gentamicin (aladdin), 10μg / mL tetracycline (aladdin), 100μg / mL Bluo gal (Thermofish), and 40μg / mL IPTG (aladdin). Uniform white spots were selected and added to 5mL LB liquid medium containing three antibiotics (50μg / mL kanamycin, 7μg / mL gentamicin, and 10μg / mL tetracycline), cultured at 37°C and 200rpm for 12-16 hours, and the recombinant bacillivirus plasmid was extracted.

[0067] TRPA1 amino acid sequence (SEQ ID NO:60):

[0068]

[0069] TRPA1 base sequence (SEQ ID NO:61):

[0070]

[0071] MSP2N2 amino acid sequence (SEQ ID NO: 62):

[0072] STFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQGTPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQE

[0073] MSP2N2 nucleotide sequence (SEQ ID NO: 63):

[0074] TCTACCTTCAGTAAACTTCGCGAACAACTGGGCCCCGTGACGCAGGAATTCTGGGACAACCTGGAAAAAGAAACCGAGGGACTGCGTCAGGAAATGTCCAAAGATTTAGAAGAGGTGAAGGCCAAGGTTCAGCCATATCTCGATGACTTTCAGAAAAAATGGCAGGAAGAGATGGAATTATATCGTCAAA AGGTGGAACCGCTGCGTGCGGAACTGCAAGAGGGGGCACGCCAAAAACTCCATGAGCTCCAAGAGAAGCTCAGCCCATTAGGCGAAGAAATGCGCGATCGCGCCCGTGCACATGTTGATGCACTCCGGACTCATTTGGCGCCGTATTCGGATGAACTTCGCCAGCGTTTGGCCGCACGTCTCGAGGCGCTG AAAGAAAACGGGGGTGCCCGCTTGGCTGAGTACCACGCGAAAGCGACAGAACACCTGAGCACCTTGAGCGAAAAAGCGAAACCGGCGCTGGAAGATCTACGCCAGGGCTTATTGCCTGTTCTTGAGAGCTTTAAAGTCAGTTTTCTGTCAGCTCTGGAAGAATATACTAAAAAGCTGAATACCCAGGGTA CCCCCGTGACGCAGGAATTCTGGGACAACCTGGAAAAAGAAACCGAGGGACTGCGTCAGGAAATGTCCAAAGATTTAGAAGAGGTGAAGGCCAAGGTTCAGCCATATCTCGATGACTTTCAGAAAAAATGGCAGGAAGAGATGGAATTATATCGTCAAAAGGTGGAACCGCTGCGTGCGGAACTGCAAGAG

[0075] 1.2 Preparation of recombinant baculovirus

[0076] Take a 6-well cell culture plate (Nest), 1×10 6 / 2mL Gibco TM sf9 insect cells were cultured in a constant temperature and humidity incubator at 27°C for 30 min, and 100 μL Insect Medium (Sf-900 TM III SFM) and add 10 μL transfection reagent (Cellfectin TMII), add 5 μg of recombinant baculovirus plasmid to another 100 μL Insect Medium, incubate at room temperature for 20 minutes after mixing, evenly add the transfection complex to a 6-well plate, continue to culture at 27°C for 72 hours, centrifuge at 4°C 6000 rpm for 15 minutes, take the supernatant, add 2% FBS, and store at 4°C in the dark to obtain the P1 generation recombinant baculovirus.

[0077] Take the P1 recombinant baculovirus and infect 2 mL of cells at a density of 5×10 5 / mL sf9 insect cells were cultured at 27°C for 72 hours, centrifuged at 6000 rpm at 4°C for 15 minutes, the supernatant was added with 2% FBS, and stored at 4°C in the dark to obtain the P2 generation recombinant baculovirus.

[0078] The separation density is 1×10 6 / mL of 40mL sf9 insect cells, cultured for 24 hours, took P2 generation recombinant baculovirus at a ratio of 1:100, cultured at 27°C, 120rpm for 96 hours, centrifuged at 4°C 6000rpm for 15 minutes, filtered the supernatant with a 0.22μm filter device, added 2% FBS, and stored at 4°C in the dark to obtain P3 generation recombinant baculovirus.

[0079] The separation density is 1×10 6 / mL of 200mL sf9 insect cells, after culturing for 24 hours, the P3 generation recombinant baculovirus was infected at a ratio of 1:100, and cultured at 27°C, 120rpm for 96 hours, centrifuged at 4°C, 6000rpm for 15 minutes, the supernatant was filtered with a 0.22μm filter device, 2% FBS was added, and stored at 4°C in the dark to obtain the P4 generation recombinant baculovirus.

[0080] Example 2 Protein Purification

[0081] HEK-293S cells were passaged at a concentration of 1.5 × 10 6 / mL, 37°C, 8% CO2, 60% humidity, 120rpm conditions for 24h, P4 generation recombinant baculovirus was used to infect HEK-293S cells at a ratio of 1:10, and sodium butyrate was added for 12-18h on a shaking platform to a final concentration of 10mM.

[0082] After 72 hours of culture, the cells were collected by centrifugation at 6000 rpm for 15 minutes at 4°C, and the cell pellet was resuspended in Lysis buffer (50 mM HEPES (Sigma-Aldrich, V900477), pH 7.4, 150 mM NaCl (Adamas, 82999B), 1% Protease Inhibitor Cocktail, EDTA-Free, 0.5% LMNG / 0.05% CHS (Anatrace, NG310-CH210), 1 mM TCEP (McLean, T819166)) and inverted for lysis at 4°C for 3 hours. After dissolution, the membrane was centrifuged at 4°C, 40,000 rpm for 45 minutes. The supernatant was tumbled and combined with MBP affinity chromatography filler (NEB, E8021L) at 4°C for 2.5 hours. The combined supernatant passed through a gravity column and the impurities were eluted with Wash buffer (25mM HEPES, pH7.4, 150mM NaCl, 1mM TCEP, 0.01% LMNG / 0.001% CHS) and washed with Elute buffer (25mM HEPES, pH7.4, 150mM NaCl, 0.01% LMNG / 0.001% CHS, 1mM TCEP, 40mM Maltose (Adamas, 73054C)) was used to elute the target protein of 100 kDa, and the target protein was concentrated with an ultrafiltration tube (Millopore, UFC910096), and packaged according to the molar ratio of TRPA1: MSP2N2: soybean lipid = 1: 3: 200. The required Soybean Polar Lipid Extract Polar (Avanti) was calculated, and the mother liquor (soybean mother liquor was 25 mg / mL) was drawn by the protein loading needle, and the soybean mother liquor was poured to the bottom of a clean and dry glass tube, and then the chloroform in the soybean mother liquor in the glass tube was blown dry with a nitrogen blower, and a little light yellow residue was formed at the bottom of the glass tube. Then add SEC buffer and sonicate for 10 minutes. During this period, the liquid in the glass tube will first appear white and turbid, then gradually become clear and finally become a light yellow solution. Add TRPA1, MSP2N2 and soybean to the EP tube in proportion and incubate on ice for 1 hour. Then add 100 mg / mL Bio-beads SM-2 (Bio-Beads TMSM-2 Resin, Bio-Rad) was used to remove detergents from the solution, and the solution was flipped at 4°C overnight. The Bio-beads SM-2 was removed by gravity column filtration, and the filtered protein solution was concentrated to a volume of 500 μL; centrifuged at 13000 rpm, 4°C for 10 min, and gel filtration chromatography was performed. The gel column model used was Superrose 6 Increase 10 / 300 GL (cytiva), and the buffer was SEC buffer (25 mM HEPES, pH 7.4, 150 mM NaCl). The protein sample was collected, the A280 concentration was tested, and the size and purity of the target protein were detected by SDS-PAGE gel electrophoresis. The SDS-PAGE gel electrophoresis diagram is shown in the figure. Figure 3 shown.

[0083] Example 3 Animal Immunization

[0084] Immunizing animals (usually mice) with antigens is the first and most important step in the preparation of monoclonal antibodies. Whether the animal's immune response to the antigen is good and whether it can produce antibodies with high titers and good specificity directly determines the difficulty of later screening of monoclonal hybridoma cell lines and the effectiveness of the antibodies obtained.

[0085] The antigen used for immunization was the protein produced by the protein preparation method of TRPA1-nanodisc in Examples 1 and 2. Balb / c, 6-8 week old female mice were selected for immunization. The amount of TRPA1-nanodics antigen used for the initial immunization was 100 μg protein / mouse, mixed with Freund's complete adjuvant at a volume ratio of 1:1, and the insufficient antigen volume was replaced with the corresponding protein purification buffer, emulsified by an oscillator, and immunized animals were routinely injected subcutaneously at multiple points on the back. After that, immunization was performed every 14 days, and the amount of antigen was half of the amount of antigen used for the initial immunization (50 μg / mouse), mixed with Freund's incomplete adjuvant at a volume ratio of 1:1, and the insufficient antigen volume was replaced with the corresponding protein purification buffer, emulsified, and routinely injected subcutaneously at multiple points on the back to immunize animals. Normally, blood is collected from mice one week after the third immunization. After the serum is separated, the serum titer is tested by ELISA (encapsulated with TRPA1-nanodics antigen, blocked with 2% BAS, and then incubated with serum diluted in a gradient (starting at 1:100, 3-fold dilution 10 times) for 1 hour, incubated with goat anti-mouse HRP (SA00001-1, proteintech) for 1 hour, and then colored with color developing solution for 10 minutes, and then the reaction is terminated with stop solution, and the absorbance value at OD450nm is tested). After that, the serum of mice is tested 7 days after each immunization. Generally, when the OD450nm value is positive at a serum dilution of 1:10000, it means that the immunization has achieved a good effect ( Figure 4 ), and subsequent experiments can be carried out.

[0086] Example 4 Cell Fusion

[0087] Cell fusion is the most important part of the hybridoma method. The fusion efficiency directly affects whether specific antibodies can be screened. Take mice with titers that meet the fusion requirements, and boost them with 100 μg of peritoneal antigen 3 days before fusion. Take spleen cells, wash them twice with serum-free and resistance-free DMEM (20 mL) culture medium, resuspend the cells with 2 mL fusion buffer after centrifugation, count and set aside. The day before fusion, myeloma cells are passaged at a ratio of 1:2. On the day of fusion, SP2 / 0 mouse myeloma cells (TCM18, Chinese Academy of Sciences Cell Bank) are collected, the culture medium is removed by centrifugation, and the cells are washed twice with serum-free and resistance-free DMEM (20 mL). After centrifugation, the cells are resuspended with 2 mL fusion buffer, counted and set aside. Take 8×10 spleen cells and SP2 / 0 cells each. 7 Cells were transferred to a new 50mL centrifuge tube, 20mL fusion buffer was added, and centrifuged together at a ratio of 1:1 (500×g for 5 minutes) twice, and then resuspended with 8mL fusion buffer and added to the electroporation cup for electrofusion. The electrofusion instrument used was the BTX ECM2001 fusion instrument, and the fusion parameters were alternating current 48V, 40s, pulse voltage: 2070V, 30μs, PF, 7S. After standing for 10min, all the fusion solution was added to the prepared 600mL culture medium, in which the main components of the culture medium were (75% DMEM + 20% FBS + 1% PS + 2% HAT (50×) + 1% Gln + 1% OPI), and cultured at 37℃ for 2h. After mixing, 42 plates were spread, with 150μL per well. On the fourth day of fusion, the culture medium with HT was completely replaced, and the supernatant was tested on the 7th day.

[0088] Example 5 Monoclonal cell screening

[0089] The screening of monoclonal cells is mainly carried out by detecting the supernatant of hybridoma cells. The detection methods mainly include ELISA and FACS. ELISA mainly tests the affinity of hybridoma supernatant to TRPA1-nanodisc antigen for immunity. After coating with 2μg / mL TRPA1-nanodisc antigen and blocking with 2% BAS, hybridoma supernatant is added for incubation for 1h, goat anti-mouse HRP is added for incubation for 1h, color development solution is added for 10min, stop solution is added to terminate the reaction, and the absorbance value of OD450nm is tested) to test the titer of serum. Through ELISA initial screening, positive hybridoma supernatants are screened and then flow screening is performed. The flow cytometer used is Beckmancoulter CytoFLEX, and the cell line used for screening is HEK293S-TRPA1. The cells to be tested are suspended cultured and passaged according to the appropriate ratio. 10μl of cells are mixed with 10μl of trypan blue, added to a hemocytometer, counted, and 5×10 5 Place cells in a 96-well V-shaped dilution plate. Centrifuge at 1500rpm for 5 minutes, tap the plate to remove the culture medium, add ELISA-positive hybridoma supernatant and incubate at 4℃ for 1 hour, wash three times with PBS, add 1:200 diluted secondary antibody (jackson, Allophycocyanin-AffiniPure F(ab')2Fragment Donkey Anti-Mouse lgG(H+L)), incubate at 4℃ for 30 minutes, wash three times with PBS, finally add 150μl PBS to each well to resuspend the cells, transfer to a 1.5mL EP tube, or directly use microtiter plate loading, Beckman CytoFLEX detection, use Cytoexpert to output the MFI value, analyze the data by the difference with the positive control and negative control, obtain positive results, perform two rounds of subcloning by limiting dilution method, and finally screen to obtain positive monoclonal cells, such as Figure 5a-5h and Figure 6a-6h shown.

[0090] Example 6 Monoclonal Antibody Preparation

[0091] The obtained positive monoclonal cells were expanded and cultured until the density reached 3×10 5 ~5×10 5 / mL inoculated 50mL serum-free culture medium for suspension culture, count the number of hybridoma cells every day, generally culture for 4-5 days, collect supernatant by centrifugation, add 200μL of ProteinA filler, flip and bind for 2-3h, affinity purification (PBS pH 7.3 equilibrium solution, glycine pH 3.0 elution solution), the purified antibody is dialyzed with PBS, the buffer is replaced, the concentration is determined and the purity of the antibody is detected by SDS-PAGE. The SDS-PAGE results are shown in Figure 7 shown.

[0092] Example 7 Monoclonal Antibody Function Test

[0093] The test of antibody function is mainly to detect calcium flow by microplate reader. The FlexStation3 multi-function plate reader produced by Molecular Devices in the United States can effectively read the fluorescence intensity changes caused by calcium ions flowing into the cell through ion channels. The HEK293T cell line with stable expression of TRPA1 was plated in 96-well plates in advance for adherent culture, grown to a suitable density, and the culture medium was discarded. At the same time, a membrane-permeable calcium ion concentration indicator (FLIPR Calcium 5Assay kit) prepared with extracellular buffer and antibody solutions of different concentrations (the concentration gradient is adjusted according to needs) were added, and the cells were incubated in an incubator for at least 60 minutes. The positive small molecule was A967079, which is a TRPA1 channel-specific inhibitor. The blank control was an extracellular buffer as a solvent, and an extracellular buffer containing a corresponding concentration of cosolvent DMSO (10% DMSO / HBSS or PBS). The whole process was kept away from light. After the incubation was completed, the 96-well plate was placed in the FlexStation3 multi-function plate reader (Molecular Devices). The TRPA1 agonist AITC (propyl isothiocyanate) sample plate was loaded into the sampler of the microplate reader in advance, and the concentration was set to 400 μM (the final concentration in the well was 100 μM). The test program was set, and the changes in the fluorescence intensity of each column of cells were immediately monitored for at least two minutes after each column of agonists was added. After all the well plates were tested, the fluorescence increments of all wells before and after the addition of the agonists were calculated based on the quantified fluorescence intensity change curve output by the machine, and the fluorescence increments of the corresponding blank control wells were normalized to obtain the inhibition rate under the action of different antibody concentrations. Two replicate wells were set for each antibody concentration, and then the inhibition curve of the logarithm of the concentration against the inhibition rate was obtained by curve fitting (Y=100 / (1+10^((LogIC50-X)*HillSlope))) in graphpad to calculate the half-inhibitory concentration IC of the antibody inhibition channel 50 , in order to determine the inhibitory effect of the antibody on TRPA1, the results are as follows Figures 8a-8i 33E8, 20D5, 38B3, 20E6, 4A11, 39C6, 33E6 and 36F6 ICs 50 They are 0.65 μM, 1.54 μM, 0.70 μM, 0.86 μM, 0.56 μM, 0.66 μM, 1.18 μM and 0.56 μM respectively.

[0094] Example 8 Antibody Sequence Acquisition

[0095] Several monoclonal antibodies were screened and hybridoma cells were revived. When the density reached 5×106 / mL, centrifuge to collect cells, extract monoclonal cell RNA using Novagen's FastPure Cell / Tissue Total RNA Isolation Kit, then use Novagen's HiScript-TS 5' / 3'RACE Kit to amplify the variable regions of the monoclonal antibody VH and VL chains using the extracted RNA as a template, recover the target band after gel electrophoresis, and measure the concentration, then use 2×Taq MasterMix to add base A at both ends of VH and VL, and finally use TaKaRa's pMDTM18-T Vector Cloning Kit to complete vector construction, after coating, pick monoclonal colonies for culture, and send for sequencing. After alignment of the sequences, the sequences of VH and VL are obtained (as shown in Table 1-8).

[0096] Table 1 33E8 antibody V sequence information

[0097]

[0098] Table 2 20D5 antibody V sequence information

[0099]

[0100] Table 3 38B3 antibody V sequence information

[0101]

[0102] Table 4 20E6 antibody V sequence information

[0103]

[0104] Table 5 4A11 antibody V sequence information

[0105]

[0106] Table 6 39C6 antibody V sequence information

[0107]

[0108] Table 7 33E6 antibody V sequence information

[0109]

[0110] Table 8 36F6 antibody V sequence information

[0111]

[0112] Among them, the CDR sequences of the heavy chain variable regions and light chain variable regions of the above antibodies 33E8, 20D5, 38B3, 20E6 and 33E6 are very similar. The present invention summarizes their CDR sequences as follows:

[0113] SEQ ID NO:56: GYX1FTDYW, wherein X1 is T or K. SEQ ID NO:57: IDSSDSYX2, wherein X2 is S or T. SEQ ID NO:58: X3RGDNSGYAI, wherein X3 is A or V. SEQ ID NO:59: QTIVHX4TGNTY, wherein X4 is S or T.

Claims

1. A TRPA1 antibody, characterized in that It includes a light chain variable region and a heavy chain variable region, wherein: The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NOs: 51-53, respectively; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 whose amino acid sequences are shown in SEQ ID NOs: 54, 30 and 55, respectively.

2. The TRPA1 antibody according to claim 1, characterized in that The heavy chain variable region also includes a heavy chain variable region framework region HFWR, and the light chain variable region also includes a light chain variable region framework region LFWR, wherein the HFWR is a heavy chain variable region framework region of human or mouse origin, and the LFWR is a light chain variable region framework region of a human or mouse antibody.

3. The TRPA1 antibody according to claim 2, wherein The light chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 50, or has at least 80% identity with the amino acid sequence as shown in SEQ ID NO: 50; and the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO: 49, or has at least 80% identity with the amino acid sequence as shown in SEQ ID NO:

49.

4. The TRPA1 antibody according to claim 3, characterized in that The TRPA1 antibody further comprises a heavy chain constant region and a light chain constant region.

5. The TRPA1 antibody according to claim 4, characterized in that The TRPA1 antibody heavy chain constant region is a human or mouse antibody heavy chain constant region; the TRPA1 antibody light chain constant region is a human or mouse antibody light chain constant region.

6. The TRPA1 antibody according to any one of claims 1 to 5, characterized in that The TRPA1 antibody is in any of the following antibody forms: (a) a complete immunoglobulin molecule; (b) a scFv; (c) a fusion protein comprising scFv; (d) a Fab fragment; (e) a Fab′ fragment; (f) a F(ab)2; Alternatively, the TRPA1 antibody is a monoclonal antibody; Alternatively, the TRPA1 antibody is a humanized antibody or a bispecific antibody. A chimeric antigen receptor comprising the TRPAl antibody according to any one of claims 1 to 6.

8. An isolated nucleic acid encoding the TRPAl antibody according to any one of claims 1 to 6, or the chimeric antigen receptor according to claim 7.

9. The isolated nucleic acid according to claim 8, wherein The nucleic acid comprises the polynucleotide sequence shown in SEQ ID NO: 47 and the polynucleotide sequence shown in SEQ ID NO:

48.

10. A recombinant expression vector comprising the isolated nucleic acid according to claim 8 or 9.

11. A transformant comprising the recombinant expression vector according to claim 10 in a host cell. 12 . A method for preparing a TRPAl antibody, comprising culturing the transformant according to claim 11 and obtaining the TRPAl antibody from the culture. 13 . An antibody-drug conjugate comprising a cytotoxic agent and the TRPAl antibody according to any one of claims 1 to 6 . 14 . A pharmaceutical composition comprising the TRPA1 antibody according to any one of claims 1 to 6, the chimeric antigen receptor according to claim 7 or the antibody-drug conjugate according to claim 13, and a pharmaceutically acceptable carrier. 15 . A kit comprising the TRPA1 antibody according to any one of claims 1 to 6, the chimeric antigen receptor according to claim 7, the antibody drug conjugate according to claim 13 and / or the pharmaceutical composition according to claim 14.

16. A method for detecting TRPA1, comprising contacting a sample with the TRPA1 antibody according to any one of claims 1 to 6, the chimeric antigen receptor according to claim 7, the antibody-drug conjugate according to claim 13, the pharmaceutical composition according to claim 14 and / or the kit according to claim 15; The detection is for non-diagnostic purposes.